Cognitive performance of 20 healthy humans supplemented with L-homoarginine for 4 weeks
Standard
Cognitive performance of 20 healthy humans supplemented with L-homoarginine for 4 weeks. / Schönhoff, Mirjam; Weineck, Gabriele; Hoppe, Julia; Hornig, Sönke; Cordts, Kathrin; Atzler, Dorothee; Gerloff, Christian; Böger, Rainer; Neu, Axel; Schwedhelm, Edzard; Choe, Chi-Un.
in: J CLIN NEUROSCI, Jahrgang 50, 04.2018, S. 237-241.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cognitive performance of 20 healthy humans supplemented with L-homoarginine for 4 weeks
AU - Schönhoff, Mirjam
AU - Weineck, Gabriele
AU - Hoppe, Julia
AU - Hornig, Sönke
AU - Cordts, Kathrin
AU - Atzler, Dorothee
AU - Gerloff, Christian
AU - Böger, Rainer
AU - Neu, Axel
AU - Schwedhelm, Edzard
AU - Choe, Chi-Un
N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.
PY - 2018/4
Y1 - 2018/4
N2 - l-homoarginine (l-hArg) is an endogenous non-proteinogenic amino acid. Low l-hArg concentrations are associated with increased all-cause mortality, fatal strokes, and worse outcome after stroke. On the other hand, oral supplementation with l-hArg in mice improved neurological deficits and preserved cardiac function in experimental models of stroke and heart failure, respectively. Recently, oral supplementation with 125 mg daily l-hArg capsules in healthy volunteers demonstrated increased l-hArg plasma levels. Therefore, oral l-hArg supplementation could represent a potential treatment for patients with cerebrovascular disease. In addition to vascular physiology, animal studies have suggested that l-hArg might play a role in synapse function, neurotransmitter metabolism and cognitive training. However the direct influence of l-hArg on cognitive function has not been studied so far. In this study, cognitive performance in healthy humans was analyzed concerning memory, learning, and attention following supplementation with placebo or l-hArg for 4 weeks. Our results did not reveal any effects on cognition, neither impairment nor improvement, upon l-hArg supplementation. Therefore, potential l-hArg treatment is not expected to cause any acute neurocognitive or behavioral side effects.
AB - l-homoarginine (l-hArg) is an endogenous non-proteinogenic amino acid. Low l-hArg concentrations are associated with increased all-cause mortality, fatal strokes, and worse outcome after stroke. On the other hand, oral supplementation with l-hArg in mice improved neurological deficits and preserved cardiac function in experimental models of stroke and heart failure, respectively. Recently, oral supplementation with 125 mg daily l-hArg capsules in healthy volunteers demonstrated increased l-hArg plasma levels. Therefore, oral l-hArg supplementation could represent a potential treatment for patients with cerebrovascular disease. In addition to vascular physiology, animal studies have suggested that l-hArg might play a role in synapse function, neurotransmitter metabolism and cognitive training. However the direct influence of l-hArg on cognitive function has not been studied so far. In this study, cognitive performance in healthy humans was analyzed concerning memory, learning, and attention following supplementation with placebo or l-hArg for 4 weeks. Our results did not reveal any effects on cognition, neither impairment nor improvement, upon l-hArg supplementation. Therefore, potential l-hArg treatment is not expected to cause any acute neurocognitive or behavioral side effects.
KW - Journal Article
U2 - 10.1016/j.jocn.2018.01.035
DO - 10.1016/j.jocn.2018.01.035
M3 - SCORING: Journal article
C2 - 29396070
VL - 50
SP - 237
EP - 241
JO - J CLIN NEUROSCI
JF - J CLIN NEUROSCI
SN - 0967-5868
ER -
